


Use of Bupropion in the Treatment of Sexual Dysfunction

Patent Highlight

Gerard Rosse*

Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121

Patent/Patent Application Number:	WO 2012/028834 A1	Publication Date:	March 8, 2012
Priority Application:	WO 2010-GB1649	Priority Date:	September 1, 2010
Inventors:	Bartels, M. P. M.; Llewellyn D.		
Assignee Company:	Individual inventors		
Disease Area:	Sexual Dysfunction	Mechanism of Action:	Dopamine and Norepinephrine Reuptake Inhibitor and Releaser
Summary:	Initially marketed as an antidepressant (Wellbutrin), bupropion was subsequently found to be effective as a smoking cessation aid (Zyban). Bupropion serves as a nontricyclic antidepressant. Its potential to cause seizure and cardiovascular problems has been widely publicized. In contrast to most commonly prescribed antidepressants such as selective serotonin reuptake inhibitors (SSRIs), it does not cause weight gain or sexual dysfunction. In 2012 and following a cardiovascular safety trial, bupropion in combination with naltrexone was approved by the FDA as Contrave to treat obesity. This patent application reported the use of bupropion in a novel indication supported by many scientific publications, treatment of both male and female sexual dysfunction.		
Important Compound Classes:	Aminoketones		
Key Structures:			



Recent Review Articles:	Demyttenaere, K.; Jaspers, L. Bupropion and SSRI-induced side effects. <i>J. Psychopharmacol.</i> 2008 , <i>22</i> (7), 792–804.
Additional Information:	New patent application for known drug

AUTHOR INFORMATION

Corresponding Author

*Address: 7473 Lusk Boulevard, San Diego, California 92121, United States. Email: grosse@dartneuroscience.com.

Notes

The authors declare no competing financial interest.

Published: August 27, 2012